Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 June, 2017 04:02 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
V-Mart Retail opens new store in Uttar Pradesh - 26-Jun-2017 13:23
ALTBalaji to be available on Opera TV powered devices globally - 26-Jun-2017 13:12
Sterlite Tech selected for Kakinada smart city project - 26-Jun-2017 13:03
Crest Ventures acquires 6 lakh shares of Crest Wealth Management - 26-Jun-2017 10:39
JK Cement gets nod to raise up to Rs 10 bn - 26-Jun-2017 09:01
Piramal Enterprises gets nod to raise up to Rs 1.25 bn - 23-Jun-2017 16:00
Bajaj Finance raises Rs 6 bn through issue of NCDs - 23-Jun-2017 11:04
ABAN Offshore arm bags order from Brunei Shell Petro for 5 years - 23-Jun-2017 10:47
Wockhardt settles ongoing commercial litigation with Teva - 23-Jun-2017 10:34
EID Parry's division forges partnership with Synthite Ind - 23-Jun-2017 10:28
Shriram EPC secures multiple orders worth Rs 1.65 bn - 23-Jun-2017 09:41
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer